 (Chest 1995; 107:662-68) 
erwise, two muscle biopsy specimens were obtained from the muscle underlying the incision in the upper (13%) or lower leg (37%). A 5X10-mm full-thickness skin biopsy specimen was taken from the margin of the skin excision. Each specimen was divided; one half was snap frozen and the other half was fixed, processed, and embedded in paraffin. Ten frozen sections were cut from each snap-frozen tissue sample and examined under polarized light for the presence of birefringent cholesterol crystals. Twelve sections were cut from each paraffin block, stained with hematoxylineosin, and examined for the presence of cholesterol emboli.
Statistical Analysis
Patient data are reported as the mean ± 1SD. Thrombolytic and nonthrombolytic patient groups were compared using unpaired two-tailed t tests and x2 analysis. Biopsy-positive and biopsynegative groups were compared using Fisher's exact test when expected frequencies were less than 5. A p value of <0.05 was considered statistically significant.
RESULTS

Clinical Characteristics
Patients receiving thrombolytic therapy had higher creatine kinase values (2,441 IU/L vs 981 IU/L, p=0.002) and were more likely to have Q-wave infarction (52% vs 19%, p=0.02) compared with the nonlytic group (Table 1) . (Review of records of nonlytic group patients confirmed that the most common reason for withholding thrombolytic therapy was lack of definite electrocardiographic criteria for acute myocardial infarction. These patients evolved fewer electrocardiographic abnormalities such as Q-waves.) Other characteristics, including age, gender distribution, presence of peripheral vascular disease, extent of coronary disease and revascularization, and complications of bypass surgery were similar between the thrombolytic and nonthrombolytic groups.
Cholesterol Embolization
Clinical evidence of cholesterol embolization (slight toe discoloration) was observed in one patient (Fig 1) . Follow-up several months later revealed no permanent sequelae.
Cholesterol embolization was not found in any skin biopsy specimen (Table 2) . Muscle biopsy specimens revealed cholesterol embolization in four patients in the thrombolytic therapy group and three patients in the nonthrombolytic therapy group (14% vs 10%, p=NS). In all seven patients in whom biopsy evidence of cholesterol embolization was found, emboli (Fig 2) , and six of the seven patients had emboli observed in paraffin block sections (Fig 3) . When emboli were present in a specimen, they were not observed in all sections from the specimen. Emboli were found in an average of 60% of frozen sections and in 70% of paraffin block sections from positive specimens. Biopsy-positive and biopsy-negative patients were compared with respect to clinical characteristics, serum creatinine values, and eosinophil counts (Table   3 ). There were no differences in clinical characteristics or eosinophil counts, but biopsy-positive patients more frequently had abnormal initial creatinine values (57% vs 15%, p=0.025). There were no significant differences between biopsy-positive and biopsy-negative patients in the incidence of creatinine level rise during hospital admission (43% vs 19%, p=0.17) or in the incidence of a concomitant rise in eosinophil count and creatinine level during hospital admission (14% vs 8%, p=NS).
DISCUSSION
The major finding of this study is that peripheral cholesterol embolization does not occur frequently after thrombolytic therapy. While peripheral cho- lesterol embolization may occur occasionally after thrombolytic therapy with clinically evident results, there is not a corresponding subclinical or clinically unrecognized embolic process that occurs routinely as a result of thrombolytic therapy. The overall 12% prevalence of cholesterol embolization in our patients was more likely due to cardiac catheterization and underlying aortic atherosclerosis than to thrombolytic therapy.
This study also provides the first prospective survey of the prevalence of peripheral cholesterol embolization in patients undergoing cardiac catheterization. The 12% prevalence found in this study is intermediate between 25% prevalence found at autopsy of previously catheterized patients23 and the 1% prevalence observed in consecutive renal biopsy specimens. 24 
Etiology of Cholesterol Embolism
Cholesterol embolism occurs in patients with diffuse atherosclerosis, but mechanisms that precipitate discrete episodes of embolism are unclear. Any event that exposes the soft lipid core of an atherosclerotic plaque to the systemic circulation can potentially cause cholesterol embolism. Nineteen patients have been described with cholesterol embolization temporally related to thrombolytic therapy (Table 4) . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The proposed cause in these patients is dissolution by the lytic agent of thrombus overlying ruptured atherosclerotic plaque, thereby exposing the inner lipid pool to the systemic circulation. However, neither this mechanism nor a causal relationship between thrombolytic therapy and cholesterol embolization has been proved. Several large thrombolytic trials have not reported any patients with cholesterol embolization.16120 To our knowledge, no previous study has prospectively assessed cholesterol embolization in patients undergoing thrombolytic therapy. 
NS
Cardiac catheterization has been associated with cholesterol embolization in individual case reports. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The proposed mechanism in these cases is mechanical disruption of atherosclerotic plaques by a guidewire or catheter, exposing the soft inner lipid pool to the systemic circulation. To our knowledge, no study has assessed the prevalence of cholesterol embolization in patients surviving cardiac catheterization. Ramirez et a123 identified cholesterol embolization at autopsy in 25% of patients with recent catheterization, compared with 2 to 10% in other series of unselected autopsies. [39] [40] [41] [42] Our study found cholesterol embolization in 14% of patients treated with thrombolytic therapy and in 10% of patients without thrombolytic therapy (p=NS). This does not suggest a relationship between cholesterol embolization and thrombolytic therapy. The overall prevalence of cholesterol embolization of 12% in this study was less than the 25% observed in the autopsy study by Ramirez et a123 of patients who had undergone cardiac catheterization. The lower prevalence in our patients may reflect a lesser degree of atherosclerosis and prior cholesterol embolization than that which led to the ultimate death of the patients of Ramirez firm their observation that cholesterol embolization may occur without severe clinical complications. All seven of our patients with biopsy specimen-proved cholesterol embolization followed a benign course without renal failure, death, gangrene, or severe skin complications. The high prevalence of baseline renal insufficiency in biopsy-positive patients in this study probably reflects a shared etiology of severe peripheral atherosclerotic disease.
Diagnosis of Cholesterol Embolization
Cholesterol embolization is notoriously hard to diagnose because of its nonspecific manifestations. One autopsy study identified 25 cases of widespread cholesterol embolization, none of which was identified clinically premortem.39 Cholesterol embolization was suspected in only 31% of 221 patients with autopsy evidence of it in a later series.43 Our prospective study confirms these retrospective findings. Although we examined and followed up patients specifically for this complication, clinical findings of cholesterol embolization were found in only one of seven (14%) patients with positive biopsy specimens.
Limitations of the Study
Our study has several limitations. Tissue Sampling: The incidence of cholesterol embolization in this study (12%) is less than would be expected from the autopsy data of Ramirez et al.23
Our patients may have had less severe, diffuse, or chronic vascular disease than that which led to the death of patients in autopsy series. Alternatively, the lower incidence observed in our study may reflect more limited tissue sampling in live patients compared with that available at autopsy. However, we obtained biopsy specimens of the same size as in studies reporting that lower extremity muscle is the most sensitive biopsy site for cholesterol emboli.
Maurizi et a142 found that biopsy of the vastus lateralis or peroneus longus was 100% sensitive, much more sensitive than biopsy of any other single organ for cholesterol embolus. Anderson and Richards4l reported that biopsy of the quadriceps or gastrocne- Ar ofAk-Thrombolytic Drug: Some case reports describing cholesterol embolization after thrombolytic therapy involved streptokinase5'12"14"15 or anisoylated plasminogen streptokinase activator complex"12 rather than tissue plasminogen activator.3'4'13 The results of this study with tissue plasminogen activator cannot be generalized to other thrombolytic drugs.
Type II Error: While our study does not support the hypothesis that thrombolytic therapy predisposes to cholesterol embolization, larger studies would be needed to exclude the possibility of a type II error (failure to detect a true difference between the groups). Assuming a 10% baseline prevalence of cholesterol embolization in our nonthrombolytic patients, retrospective power calculations suggest that our study population would have been large enough to detect a 40% prevalence of cholesterol embolization in the thrombolytic group (power=0.8, p=.05, two-tailed test). Retrospective power calculations, assuming that the difference we observed between the groups (10% vs 14%) was real, suggest that 685 patients would need to be enrolled in each arm to demonstrate statistical significance (power=0.80, p=0.05, two-tailed test). Even if a larger study associated cholesterol embolization with thrombolytic therapy, the benign course of our patients suggests that clinically it would rarely be important.
CONCLUSIONS
To our knowledge, this is the first prospective study to assess the prevalence of cholesterol embolization in coronary disease survivors who have undergone catheterization. The prevalence in our patients (12%) is intermediate between the 1 to 10% seen in unselected autopsy series and the 25% observed in patients who died after catheterization.
This study does not demonstrate a significantly higher prevalence of cholesterol embolization in patients receiving thrombolytic therapy than in patients treated conservatively. A weak relationship between thrombolytic therapy and cholesterol embolization cannot be excluded, but our finding that most cholesterol embolization is subclinical suggests that any such relationship would be of very limited clinical significance. Isolated case reports of severe cholesterol embolization temporally associated with thrombolytic therapy do not represent a phenomenon that has widespread subclinical occurrence.
